Kenya Will Build A Vaccine Manufacturing Plant In Nairobi Worth USD 17 Million

Kenya Post
COVID-19 Manufacturing & Supply Chain SARS-CoV-2 Vaccine Development Vaccine Development Vaccine Outreach to Developing Economies

Kenya Will Build A Vaccine Manufacturing Plant In Nairobi Worth USD 17 Million

Kenya will spend USD 17 million billion to build a vaccine production plant. According to Health Cabinet Secretary Mutahi Kagwe, the company, Kenya Biovax Limited will begin operations as a “fill and finish” plant under the Ministry of Health in the next six months.

According to Kagwe, the majority of the fund would be used to purchase equipment which has previously relied on donations, and it will produce its own vaccinations in Kenya. 

In addition, Kagwe mentioned that this investment should have been done a long time ago as the danger of relying on other countries for vaccines.Kagwe added Kenya has the ability to research and manufacture animal vaccines but don’t have the ability to produce human vaccines, which is a curious thing. 

By Easter next year, the president authorized the Ministry of Health to operationalize the facility for the ultimate manufacture of homespun doses.

According to the National COVID-19 Vaccine Deployment Plan, Kenya expects to have fully functional vaccine production capability by 2024.

(Source: Mwakilishi, 2021)

Leave a Reply